interconnected strategy , leading to resilience , competitiveness , and sustained business growth over multiple years . The company ’ s robust business model proved its worth by generating optimal returns in favorable market conditions and standing strong during industry downturns . However , the ultimate aim isn ' t just about this resilience ; it ' s to amplify value for everyone involved . The company ' s strong foundation lies in key elements : achieving extensive scale , operating at minimum costs , securing the highest margins , focusing on sales in regulated markets , backward integration and paving the way for sustainable growth . By adhering to these principles , our goal is to optimize value for stakeholders and ensure long-term success .
What are your India plans for 2024 ? Looking ahead , what do you see as the key opportunities ?
India is an indispensable market to West and we maintain strong commitment with reputable position here . We aim to bring and inspire more innovation , grow team and talents , give back to the local communities as we grow together with the customers , the industry , and the country .
With emerging treatments coupled with a rapidly changing society , it is imperative to understand evolving patient needs and find solutions that cater to them . The pandemic was a learning experience where most thriving businesses had to pivot strategies and find innovative solutions . The GMP Annex 1 revisions was another hint that regulators around the world are
“ The global cancer market is estimated at U . S $ 21.5 billion , and the company is expecting to create a 1 % to 2 % market share .” demanding increasing levels of quality . Drug developers are more in need of a trusted partner that is capable to support the contamination control strategy and help them navigate the new regulations successfully .
As a collective biomedical market , we are now moving out of siloed , traditional ways of working . Instead , there will arise more opportunities for collaboration and partnerships between different stakeholders to drive innovation and development . I believe we enjoy the opportunity to deliver more impactful solutions with our strong partnerships , like Daikyo and Corning , and in 2024 , we are in a good position to take on effective collaboration with valued partners from around the world .
BioTech
BIOVOICENEWS . COM 57